Journal Home
Search for

Volume 47, Issue 4, Pages 514-520 (October 2007)


View previous. 21 of 36 View next.

Association between consumption of Herbalife® nutritional supplements and acute hepatotoxicity

Eran Elinav1, Galia Pinsker4, Rifaat Safadi1, Orit Pappo2, Michal Bromberg4, Emilia Anis4, Lital Keinan-Boker4, Efrat Broide5, Zvi Ackerman3, Dorit Nitzan Kaluski4, Boaz Lev4, Daniel Shouval1Corresponding Author Informationemail address

Received 19 April 2007; received in revised form 4 June 2007; accepted 6 June 2007. published online 02 August 2007.

Background/Aims

Nutritional supplements are frequently considered to be harmless but indiscriminate use of unlabelled ingredients may lead to significant adverse reactions.

Methods

In 2004, identification of four index cases of acute hepatitis associated with Herbalife® intake led to a ministry of health investigation in all Israeli hospitals. Twelve patients with acute idiopathic liver injury in association with consumption of Herbalife® products were investigated.

Results

Eleven of the patients were females, aged 49.5±13.4 y. One patient had stage I primary biliary cirrhosis and another had hepatitis B. Acute liver injury was diagnosed after 11.9±11.1 months of initiation of Herbalife® consumption. Liver biopsies demonstrated active hepatitis, portal inflammation rich with eosinophils, ductular reaction and parenchymal inflammation with peri-central accentuation. One patient developed sub-fulminant and two fulminant episodes of hepatic failure. Hepatitis resolved in eleven patients, while one patient succumbed to complications following liver transplantation. Three patients resumed consumption of Herbalife® products following normalization of liver enzymes, resulting in a second bout of hepatitis.

Conclusions

An association between intake of Herbalife® products and acute hepatitis was identified in Israel. We call for prospective evaluation of Herbalife® products for possible hepatotoxicity. Until then, caution should be exercised by consumers, especially among individuals suffering from underlying liver disease.

Associate Editor: C.P. Day

1 Liver Unit, Hadassah-Hebrew University Medical Center, Ein-Kerem, P.O. Box 12000, Jerusalem 91120, Israel

2 Department of Pathology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel

3 Department of Medicine, Hadassah-Hebrew University Medical Center, Jerusalem, Israel

4 Ministry of Health, Israel

5 Institute of Gastroenterology, Assaf Harofeh Medical Center, Zerifin, Israel

Corresponding Author InformationCorresponding author. Tel.: +972 2 6777 337; fax: +972 2 6420338.

 The authors who have taken part in this study declared that they do not have anything to disclose regarding conflict of interest with respect to this manuscript.

PII: S0168-8278(07)00367-4

doi:10.1016/j.jhep.2007.06.016


View previous. 21 of 36 View next.